Cargando…
Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events
Background: Immune-related adverse events (iRAEs) are known complications of immune checkpoint inhibitors (ICIs). Early identification and management leads to improved morbidity and mortality. This study seeks to address our center’s experience with iRAEs in the emergency department (ED). Methods: W...
Autores principales: | Holstead, Ryan, Kartolo, Adi, Baetz, Tara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816173/ https://www.ncbi.nlm.nih.gov/pubmed/33704174 http://dx.doi.org/10.3390/curroncol28010007 |
Ejemplares similares
-
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022) -
Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
por: Kartolo, Adi, et al.
Publicado: (2022) -
Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
por: Castillo, Richmond M., et al.
Publicado: (2021) -
38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021) -
Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)